The Primacy of Public Health Considerations in Defining Poor Quality Medicines

1. Wellcome Trust 2009 Opinion formers' conference on counterfeit medicines: perspectives and action. Available: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/WTX057518.pdf. Accessed 10 October 2011

2. Fondation Chirac 2009 The Cotonou Declaration. Available: http://www.fondationchirac.eu/en/the-cotonou-declaration-october-12-2009-benin/. Accessed 10 October 2010

3. NewtonPNGreenMDFernándezFMDayNJPWhiteNJ 2006 Counterfeit anti-infective medicines. Lancet Infect Dis 6 602 613

4. NewtonPNMcGreadyRFernandezFGreenMDSunjioM 2006 Manslaughter by fake artesunate in Asia–will Africa be next? PLoS Med 3 e197 doi:10.1371/journal.pmed.0030197

5. NewtonPNGreenMDFernándezFM 2010 Impact of poor-quality medicines in the ‘developing’ world. Trends Pharmacol Sci 31 99 101

6. ShepherdM 2010 Beef up international cooperation on counterfeits. Nat Med 16 366

7. CaudronJMFordNHenkensMMacéCKiddle-MonroeR 2008 Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Hlth 13 1062 1072

8. ParkCS 2009 Legal aspects of defining “counterfeit medicines”: a discussion paper. WHO-SEARO.

9. World Health Organization 2008 Executive Board 124th session provisional agenda item 4.11. Counterfeit medical products. EB124/14. Available: http://www.who.int/gb/ebwha/pdf_files/EB124/B124_14-en.pdf. With corrigendum: http://apps.who.int/gb/ebwha/pdf_files/EB124/B124_14Corr1-en.pdf. Accessed 10 October 2011

10. SimonsB 24 February 2009 Vested interests in fake drugs. AfricanLiberty.org. Available: http://www.africanliberty.org/node/640. Accessed 27 October 2011

11. LiangBA 2008 Counterfeit drugs–defining the problem Vienna (Virginia) Partnership for Safe Medicines Available: http://www.safemedicines.org/2008/07/defining-the-problem.html. Accessed 10 October 2011

12. [No authors listed] 14 January 2009 OPPI, IDMA come out with contrasting views on definition of counterfeit drugs. Pharmaquest. Available: http://www.pharmaquest.biz/Policy-and-Regulations/Important-Report/OPPI-IDMA-come-out-with-contrasting-views-on-definition-of-counterfeit-drugs.html. Accessed 3 November 2011

13. HarrisJ 5 December 2008 New definition of fake drugs envisages better health. The Pioneer. Available: http://www.policynetwork.net/health/media/new-definition-fake-drugs Accessed 3 November 2011

14. ShuklaNSangalT 2009 Generic drug industry in India: the counterfeit spin. J Intell Prop Rights 14 236 240 Available: http://nopr.niscair.res.in/bitstream/123456789/4192/1/JIPR%2014(3)%20236-240.pdf. Accessed 10 October 2011

15. CliftC 2010 Combating counterfeit, falsified and substandard medicines: defining the way forward? Chatham House Briefing Paper. Available : http://www.chathamhouse.org/publications/papers/view/109517. Accessed 27 October 2011

16. ShrivastavaB 23 May 2008 India fears generic drugs may be hit by fake medicine definition. Livemint.com. Available: http://www.livemint.com/2008/05/23004023/India-fears-generic-drugs-may.html?d=1. Accessed 10 October 2011

17. TaylorL 31 March 2010 India chides WHO over ‘counterfeit’ drugs. PharmaTimes. Available: http://www.pharmatimes.com/WorldNews/article.aspx?id=17638. Accessed 10 October 2011

18. DeySSinghK 27 January 2009 WHO won't redefine fake drugs. Economic Times. Available: http://articles.economictimes.indiatimes.com/2009-01-27/news/27645724_1_counterfeit-drugs-generic-drug-legitimate-generic-medicines. Accessed 27 October 2011

19. ShashikantS 16 January 2009 WHO: approach to “counterfeit” drugs may affect access to medicines. TWN Info Service on Intellectual Property Issues (Jan09/01). Published in SUNS #6618 dated 15 January 2009. Third World Network. Available: http://www.twnside.org.sg/title2/intellectual_property/info.service/2009/twn.ipr.info.090101.htm. Accessed 27 October 2011

20. Third World Network 2010 Briefing paper 2. WHOs “counterfeit” programme: legitimises IP enforcement agenda, undermines public health. Available: http://www.twnside.org.sg/title2/briefing_papers/nontwn/Briefing.paper.on.WHO.Counterfeits.pdf. Accessed 10 October 2011

21. ArrowKJPanosianCBGelbandH 2004 Saving lives, buying time: economics of malaria drugs in an age of resistance Washington (D.C.) Institute of Medicine of the National Academies Available: http://www.nap.edu/books/0309092183/html/. Accessed 10 October 2011

22. LonCTTsuyuokaRPhanouvongSNivannaNSocheatD 2006 Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg 100 1019 1024

23. Oxfam 2011 Eye on the ball. Medicine regulation – not IP enforcement – can best deliver quality medicines. Available: http://www.oxfam.org.nz/resources/onlinereports/BP143-Eye-on-the-Ball-Medicine-Regulation-020211-summ-en.pdf. Accessed 10 October 2011

24. Médecins sans Frontières 2010 Patients first: access to safe, quality and effective drugs. Available: http://www.msfaccess.org/sites/default/files/MSF_assets/Access/Docs/ACCESS_briefing_PatientsFirst_CounterfeitWHA_ENG_2010.pdf. Accessed 10 October 2011

25. Third World Network 11 May 2010 NGO open letter over WHO's involvement in “counterfeit medical products” & in the IMPACT. Available: http://www.twnside.org.sg/announcement/Open.Letter.to.WHO.DG.final.PDF. Accessed 10 October 2011

26. World Health Organization 2010 Draft resolution proposed by the delegation of Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Cote d'Ivoire, Equatorial Guinea, Ethiopia, Gabon, Gambia, Ghana, Guineea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, mali, Mauritius, Namibia, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. Agenda item 11.20. Sixty-third World Health Assembly A63/A/Conf.Paper No. 5. 19 May 2010

27. World Health Organization 2010 Draft resolution proposed by the delegation of India and Thailand. Sixty-third World Health Assembly A63/A/Conf.Paper No. 7 18 May 2010

28. World Health Organization 2010 Substandard/spurious/falsely labelled/falsified/counterfeit medical products. Draft decision of the Working Group. Sixty-third World Health Assembly Agenda Item 11.20. 21 May 2010

29. World Health Organization 2011 Substandard/spurious/falsely-labelled/falsified/counterfeit medical products. Report by the Director General. 24th March 2011. Available: http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_16-en.pdf. Accessed 10 October 2011

30. CurraisLRiveraBRungoP 2008 Potential conflicts in the fight against counterfeit drugs. Economics Bulletin 9 1 7 Available: http://www.accessecon.com/pubs/EB/2008/Volume9/EB-08I10002A.pdf. Accessed 10 October 2011

31. PisaniE 2011 IFPMA: building a consensus to address the health threat posed by fake medicines. Available: http://www.essentialdrugs.org/edrug/archive/201103/msg00001.php. Accessed 10 October 2011

32. The International Federation of Pharmaceutical Manufacturers & Associations 2010 The IFPMA ten principles on counterfeit medicines. Available: http://www.ifpma.org/fileadmin/content/Global%20Health/Counterfeits/IFPMA_Ten_Principles_Counterfeit_Medicines_12_May_2010.pdf. Accessed 10 October 2011

33. AttaranABateRKendallM 2011 Why and how to make an international crime of medicine counterfeiting. J Int Criminal Justice 9 325 354 doi:10.1093/jicj/mqr005

34. World Health Organization 2009 What are substandard medicines? Available: http://www.who.int/medicines/services/counterfeit/faqs/06/en/index.html. Accessed 10 October 2011

35. World Health Organization 2010 New definition for “substandard medicines”. Working document QAS/10.344/Rev.1. Available: http://www.who.int/medicines/services/expertcommittees/pharmprep/14052010NewDefinitionSubstandardMeds-QAS10-344Rev1.pdf. Accessed 10 October 2011